Language

Chinese English

Conference Information

Home page

Innovation is shifting eastward—where does regulation stand?

Mar 27,2026

The United States and China in the New World Order

Multinational Pharmaceutical Companies Are “Increasing Their Positions” in China

Mar 25,2026

A Vote of Confidence Worth Over Hundreds of Billions

8 Billion in M&A Within Two Days: China’s Innovative Drugs Are Becoming Global “Hard Currency”

Mar 25,2026

Making Its Way to the Center of the Global Stage

Chinese Pharmaceutical Companies “Challenge” the World’s Most Expensive

Mar 24,2026

Full-Scale Pursuit

The Inaugural CNS Innovative Drug R&D Conference Is Here | CPIC Global Conference

Mar 23,2026

As the inaugural featured conference, The 1st CNS Innovative Drug R&D Conference is co-hosted by TONACEA, Hanshu Bio, and Quark Pharma. Focusing on the high-value, high-potential sector of CNS drug development, the conference brings together top R&D experts from around the world to decode emerging CNS targets and mechanisms, clinical development, gene editing, and other key technologies. It will feature in-depth discussions on cutting-edge topics such as the treatment of CNS diseases and global registration strategies for innovative drugs, aiming to establish a professional exchange platform for R&D innovation, clinical translation, industrial collaboration, and global partnership in the CNS field.

Blueprint for the Conference Unveiled! The Inaugural Global Summit on Innovative Drugs from Major Countries to Create a Chinese Version of JPM

Mar 22,2026

The conference is benchmarked against the J.P. Morgan Healthcare Conference, establishing a model of "China Innovation—Global Translation—Shanghai Exchange." It aims to highlight China's status as a major player in new drugs and drive Chinese innovation to lead the global health industry.

Zhu Xun: It’s Time for China’s Innovative Drugs to Shift from “R&D Stories” to “Profit Stories”

Mar 21,2026

The logic, challenges, and ways to break through the frenzy of going out to sea

The Chinese GLP-1 market is about to undergo a major shift.

Mar 20,2026

Semaglutide patent expiration

< 1...11 12 13 14 > proceed page